期刊文献+

艾塞那肽联合二甲双胍治疗对2型糖尿病患者血管内皮功能的影响 被引量:1

Effect of exenatide combined with metformin on vascular endothelial function in patients with type 2 diabetes
下载PDF
导出
摘要 目的:分析艾塞那肽联合二甲双胍治疗对2型糖尿病患者血管内皮功能的影响。方法:选取2015年9月至2017年8月我院收治的2型糖尿病患者120例,按照治疗方式分为观察组和对照组,对照组采用二甲双胍治疗,观察组在对照组的基础上联合艾塞那肽治疗,比较两组治疗效果。结果:观察组治疗后内皮依赖性血管舒张功能(EDD)高于对照组(P<0.05);两组治疗后内皮非依赖性血管舒张功能(NMD)差异无统计学意义(P>0.05)。观察组患者治疗后空腹血糖、餐后2h血糖、糖化血红蛋白均低于对照组(P<0.05)。结论:艾塞那肽联合二甲双胍治疗2型糖尿病可有效改善血管内皮依赖性舒张功能,控制患者血糖水平效果优于单独用药,可推广应用。
机构地区 新乡市中心医院
出处 《甘肃医药》 2018年第6期500-501,共2页 Gansu Medical Journal
  • 相关文献

参考文献8

二级参考文献79

  • 1李显丽,李奕平,王晓苓.艾塞那肽治疗肥胖2型糖尿病的临床疗效观察[J].昆明医科大学学报,2012,33(4):125-127. 被引量:4
  • 2隋婧,陈福琴.脂肪因子与2型糖尿病[J].中国老年学杂志,2007,27(20):2048-2050. 被引量:4
  • 3Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-958.
  • 4Deaton CF. What do we know about the secretion and degradation of incretin hormones[J]? Regul Pept, 2005, 128(2): 117-124.
  • 5Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes[J]. Diabetes Care, 2013, 36(10): 3276-3282.
  • 6Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU)[J]. Diabet Med, 2009, 26(3): 268-278.
  • 7Nauck MA, Frid A, Hermansen K, et al. Efficacy andsafety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus. The LEAD (Liraglutide Effect and Action in Diabetes)-2 study[J]. Diabetes Care, 2009, 32(1): 84-90.
  • 8Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial[J]. Lancet, 2009, 373(9662): 473-481.
  • 9Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD)[J]. Diabetes Care, 2009, 32(7): 1224-1230.
  • 10Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial[J]. Diabetologia, 2009, 52(10): 2046-2055.

共引文献59

同被引文献16

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部